Upfront Briefing
Sanofi and Regeneron notched another Dupixent checkbox: Japan approved dupilumab for adult bullous pemphigoid.
On the deal calendar, Galapagos and Gilead say they’re in advanced discussions on an autoimmune T cell engager collaboration, while Apogee floated a proposed $300M underwritten offering (because nothing says “confidence” like a fresh equity print).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,581.0 |
+1.1% |
(3.9%) |
| Nasdaq 100 |
24,188.6 |
+1.2% |
(4.0%) |
| Russell 2000 |
2,494.2 |
+2.3% |
+0.5% |
| Healthcare (XLV) |
144.8 |
0.0% |
(6.5%) |
| Biotech (XBI) |
121.7 |
+1.2% |
+0.1% |
| Nasdaq Biotech (NBI) |
5,623.2 |
+0.6% |
(1.5%) |
| Clinical Trials (BBC) |
39.9 |
+0.7% |
+6.0% |
|
- Biotech participated in the relief rally rather than truly leading it: XBI rose 1.2% and NBI 0.6% as the market re-priced a lower near-term oil/inflation shock after headlines pointing to a pause in U.S. strikes tied to Iran.
- Small caps led hard (Russell 2000 +2.3%), which reads as classic beta catch-up: when energy pressure eases and yields stop lurching higher, financing-sensitive, domestically exposed names usually outperform first.
- Healthcare lagged the broader risk move (XLV ~flat), suggesting Monday was more about macro relief and factor rotation than a clean sector-specific bid for defensives.
- Market data: U.S. close Monday 23-Mar-2026.
The Big 3
|
1
|
Japan approves Dupixent for bullous pemphigoid
|
- Sanofi and Regeneron said Dupixent (dupilumab) was approved in Japan to treat adults with bullous pemphigoid. The approval adds a new indication in the market.
-
Why it matters:
This is not just another label extension — it reinforces the core Dupixent investment case that value is being created through indication stacking across geographies, which helps sustain franchise-duration assumptions and lowers dependence on any single specialty market or reimbursement corridor.
- Source: PR
|
|
2
|
Apogee proposes $300M underwritten public offering
|
- Apogee Therapeutics announced a proposed $300 million underwritten public offering.
-
Why it matters:
A $300M follow-on would be a meaningful balance-sheet reset: it can extend runway through multiple value-inflection points, but investors will focus on where the book clears, the size of the discount and whether management is choosing to fund from strength or because the market is forcing an earlier dilution event.
-
Source:
PR
|
|
3
|
Gilead buys Ouro Medicines for up to $2.18B
|
-
Gilead said it will acquire privately held Ouro Medicines for $1.68B upfront in cash plus up to $500M in milestone payments, adding OM336 and related autoimmune assets to its immunology pipeline.
-
Why it matters:
This is the more important signal than “advanced discussions” alone: Gilead is actively redeploying capital into immunology, and the structure gives investors a much clearer read on how management is underwriting external innovation, platform optionality and future pipeline diversification beyond legacy franchises.
-
Source:
Reuters
|
Everything Else that broke
- Innovent says Phase 3 registration STAR study met its primary endpoint in nAMD in China. — PR
- Prestige Biopharma posts positive Phase 3 topline for HD204, a potential Avastin biosimilar. — PR
- Karyopharm says its blood-cancer drug met one of two main late-stage study goals, improving spleen volume but missing symptoms. — Reuters
- Pfizer and Valneva say their Lyme vaccine showed >70% efficacy but missed a key statistical goal; companies still plan to file. — Reuters
- Roche launches cobas eplex respiratory pathogen panel 3 in CE markets. — PR
- BioCentury flags a push to decouple China–U.S. cell-therapy R&D. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Gilead to acquire Ouro Medicines for up to $2.18B to expand its immunology pipeline. — Reuters
-
Galapagos and Gilead say they are in advanced discussions on an autoimmune T-cell engager collaboration. — PR
-
Sanofi licenses Kali Therapeutics’ clinical tri-specific autoimmune T-cell engager KT501; $180M upfront/near-term, up to $1.05B in milestones plus tiered royalties. — PR
VC / Private Financings
-
Immutrin raises £65M ($87M) Series A for ATTR amyloidosis; led by Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise. — PR
-
Laigo Bio completes €17M oversubscribed seed; co-led by Biovance Capital and Kurma Partners, with support from Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons. — PR
-
Oryon Cell Therapies launches with $21M in new funding to advance an autologous Parkinson’s cell therapy; backed by Neuro.VC, Byers Capital and others. — Reuters
IPOs / Follow-Ons
-
Apogee proposes $300M underwritten public offering. — PR
Academic Corner
- Enhancing CAR-NK cell efficacy in solid tumours. — Nature RDD
- Wearable technologies in clinical trials for drug development: trends and emerging opportunities. — Nature RDD
- Can a first disease-modifying osteoarthritis drug make it past the FDA?. — Nature RDD
|
